Drug
Cenerimod
Cenerimod: highest development phase Phase 3, developed by Viatris. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cenerimod NCT05648500 | Phase 3 | Lupus Erythematosus, Systemic |
| Cenerimod NCT05672576 | Phase 3 | Lupus Erythematosus, Systemic |
| Cenerimod NCT07201129 | Phase 3 | Nephritis, Lupus |
| Cenerimod NCT06475742 | Phase 3 | Lupus Erythematosus, Systemic |
| Cenerimod NCT02472795 | Phase 1/2 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Cenerimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.